Pubdate: Mon, 01 Nov 2004
Source: Charleston Gazette (WV)
Copyright: 2004 Charleston Gazette
Contact:  http://www.wvgazette.com/
Details: http://www.mapinc.org/media/77
Author: Toby Coleman, Staff writer
Bookmark: http://www.mapinc.org/find?232 (Chronic Pain)
Bookmark: http://www.mapinc.org/oxycontin.htm (Oxycontin/Oxycodone)

OXYCONTIN MARKETING TACTICS GO ON TRIAL TODAY

WELCH - Today, lawyers working for the state and a massive drug maker will 
begin picking the jurors who may determine the future of the painkiller 
OxyContin in West Virginia.

The state's lawyers come to McDowell County's old stone courthouse seeking 
tens of millions of dollars they say OxyContin's maker, Purdue Pharma, owes 
West Virginia for dishonestly marketing the pain pill.

When the trial begins, the state's lawyers plan to tell jurors that the 
company kept doctors, pharmacists and patients in the dark about the 
morphinelike drug's addictive qualities because it wanted to sell more 
pills, according to court filings and hearing transcripts.

The company's lawyers say cancer patients and other chronic pain sufferers 
have found relief after using the pill.

If the jurors in this trial side with the state, the company may stop 
selling the drug in West Virginia, lawyer Timbera Wilcox told McDowell 
Circuit Judge Booker Stephens in a memorandum filed last month.

"Truly, at the end of the day this case is really about West Virginians 
continuing to get state-of-the-art" pain medication, Wilcox said in a 
recent telephone interview.

OxyContin is the world's best-selling painkiller. Purdue Pharma sold $1.9 
billion worth of the drug last year,

West Virginia Attorney General Darrell McGraw started this courtroom fight 
in 2001, about five years after Purdue Pharma began shipping OxyContin to 
West Virginia pharmacies.

By then, Purdue Pharma had turned the powerful opiate into a moneymaker. In 
2001 alone, it sold $1 billion worth of OxyContin pills. West Virginia 
state agencies bought about $7.1 million worth of pills that year, 
according to state records.

Although the company put more oxycodone in OxyContin than other commonly 
abused painkillers, it said drug users were unlikely to pop them to get 
high because the pills released the oxycodone slowly over a 12-hour period.

The company was wrong. Drug users figured out that by crushing the pills, 
they could ingest a tablet's entire oxycodone content at once. By the time 
McGraw filed his lawsuits, nearly half of the West Virginians in 
rehabilitation trying to beat an addiction to prescription pills named 
OxyContin as their drug of choice, according to state records.

For years, Purdue Pharma has maintained that it is not responsible for the 
problems caused by OxyContin abuse.

"It is safe and effective when used as intended, and that is what is 
intended by Purdue," said Wilcox, one of the company's lawyers.

The state's lawyers say the company could have actually prevented some of 
the problems caused by OxyContin abuse by telling doctors, pharmacists and 
patients more about the drug.

For instance, the company did not mention some of the drug's potentially 
fatal side effects in a handful of advertisements it ran in medical 
journals in recent years, according to the Food and Drug Administration. 
The FDA forced the company to pull the ads.

The company also told its sales force in West Virginia to downplay the 
drug' s addictive qualities, according to William Gergley. He was the 
company's district manager for West Virginia and western Pennsylvania for 
more than two decades. Purdue Pharma fired him in 2000.

"They told us to say things like it is 'virtually' nonaddicting," Gergely 
told the South Florida Sun-Sentinel last year. "That's what we were 
instructed to do. It's not right, but that's what they told us to say."

The state's lawyers say that Purdue Pharma should pay for these and other 
misleading marketing practices. They have not said how much they will ask 
the jury to award the state, but have said that their request could equal 
or exceed the $30.5 million various state agencies have spent on OxyContin 
between 1996 and 2003.
- ---
MAP posted-by: Terry Liittschwager